<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE collection SYSTEM "BioC.dtd">
<collection><source>PMC</source><date>20220802</date><key>pmc.key</key><document><id>9329707</id><infon key="license">CC BY</infon><passage><infon key="article-id_doi">10.7759/cureus.26383</infon><infon key="article-id_pmc">9329707</infon><infon key="article-id_pmid">35911257</infon><infon key="elocation-id">e26383</infon><infon key="issue">6</infon><infon key="kwd">dyshidrosiform bullous pemphigoid bullous pemphigoid covid 19 covid-19 vaccination skin side effects covid-19 vaccination</infon><infon key="license">This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</infon><infon key="name_0">surname:Muacevic;given-names:Alexander</infon><infon key="name_1">surname:Adler;given-names:John R</infon><infon key="name_2">surname:Shanshal;given-names:Mohammed</infon><infon key="notes">The content published in Cureus is the result of clinical experience and/or research by independent individuals or organizations. Cureus is not responsible for the scientific accuracy or reliability of data or conclusions published herein. All content published within Cureus is intended only for educational, research and reference purposes. Additionally, articles published within Cureus should not be deemed a suitable substitute for the advice of a qualified health care professional. Do not disregard or avoid professional medical advice due to content published within Cureus.</infon><infon key="section_type">TITLE</infon><infon key="type">front</infon><infon key="volume">14</infon><infon key="year">2022</infon><offset>0</offset><text>Dyshidrosiform Bullous Pemphigoid Triggered by COVID-19 Vaccination</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>68</offset><text>Vaccination has made a substantial contribution to global health improvement throughout history. The coronavirus disease 2019 (COVID-19) vaccinations have provided us with a ray of hope for combatting the ongoing pandemic and saving lives. However, following COVID-19 vaccination, a wide spectrum of cutaneous adverse effects have been observed. We report a case of dyshidrosiform bullous pemphigoid, a rare clinical variant of bullous pemphigoid, following COVID-19 vaccination in an elderly female patient. The biopsy revealed subepidermal splitting with positive direct and indirect immunofluorescence studies.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_1</infon><offset>682</offset><text>Introduction</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>695</offset><text>Since the World Health Organization (WHO) declared it a global pandemic in March 2020, coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has affected millions of people worldwide. The massive impact of COVID-19 has led to the world's largest immunisation campaign. All approved COVID-19 vaccinations in the UK meet strict standards of safety, quality, and effectiveness. While the COVID-19 vaccine's short-term adverse effects are similar to those of other vaccines, the vaccine's long-term side effects are still unknown, and rare systemic and cutaneous side effects continue to be reported throughout the world. Bullous pemphigoid is a rare autoimmune blistering condition characterised by the development of sub-epithelial blisters. In most cases of bullous pemphigoid, no clear triggering cause has been identified. Possible predisposing factors have been linked to the development of bullous pemphigoid, including genetic susceptibility, concurrent medical conditions, certain medications, radiotherapy, and exposure to ultraviolet light.</text></passage><passage><infon key="section_type">CASE</infon><infon key="type">title_1</infon><offset>1801</offset><text>Case presentation</text></passage><passage><infon key="section_type">CASE</infon><infon key="type">paragraph</infon><offset>1819</offset><text>The patient was a 90-year-old woman who was admitted to the hospital on 30 March 2021 with a widespread itchy eczematous rash involving the trunk and extremities, and left leg swelling. The patient was on long-term warfarin, bisoprolol, amlodipine, bendroflumethiazide, and ursodeoxycholic acid for atrial fibrillation, hypertension, and primary biliary cirrhosis, respectively. Her blood pressure medications had been initiated more than 10 years ago, and her drug list had not changed recently. The patient’s family history was unremarkable, and she had never had a skin problem before.</text></passage><passage><infon key="section_type">CASE</infon><infon key="type">paragraph</infon><offset>2413</offset><text>The eruption had begun one week after her first COVID-19 vaccination (Pfizer-BioNTech) on 29 December 2020. Her general practitioner had tried hydrocortisone 1% cream, moisturiser, oral antihistamine, and permethrin 5% for suspected scabies. However, her skin condition persisted. After her second dose on 18 March 2021, the rash worsened considerably with severe itching.</text></passage><passage><infon key="section_type">CASE</infon><infon key="type">paragraph</infon><offset>2786</offset><text>On examination, there were widespread eczematous rash and excoriation marks involving the trunk and extremities. The face, palm, soles, and mucous membranes were spared. Left leg swelling was observed and the patient was investigated for possible deep vein thrombosis (DVT). Histology of the skin lesion showed features of the chronic eczematous process with mild perivascular chronic inflammation, and occasional neutrophils and eosinophils. The initial clinical impression was of a post-vaccination eczematous rash; the patient was discharged on oral prednisolone after ruling out DVT, and this vaccine reaction was reported through the UK Yellow Card Scheme. </text></passage><passage><infon key="section_type">CASE</infon><infon key="type">paragraph</infon><offset>3450</offset><text>On 16 May, the patient was re-admitted with severe itchy and painful large intact blisters involving the palms and soles (Figure 1).</text></passage><passage><infon key="file">cureus-0014-00000026383-i01.jpg</infon><infon key="id">FIG1</infon><infon key="section_type">FIG</infon><infon key="type">fig_title_caption</infon><offset>3583</offset><text>COVID-19-triggered dyshidrosiform bullous pemphigoid</text></passage><passage><infon key="file">cureus-0014-00000026383-i01.jpg</infon><infon key="id">FIG1</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>3636</offset><text>A and B: Tense bullae involving the palms and soles. C: Extensive erosions involving the extremities</text></passage><passage><infon key="file">cureus-0014-00000026383-i01.jpg</infon><infon key="id">FIG1</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>3737</offset><text>COVID-19: coronavirus disease 2019</text></passage><passage><infon key="section_type">CASE</infon><infon key="type">paragraph</infon><offset>3773</offset><text>Histological and immunofluorescence studies showed subepidermal splitting with moderate subjacent inflammation and linear deposition of C3 along the basement membrane zone (BMZ) respectively. Circulating anti-BMZ IgG autoantibodies were detected by the indirect immunofluorescence technique (Figure 2).</text></passage><passage><infon key="file">cureus-0014-00000026383-i02.jpg</infon><infon key="id">FIG2</infon><infon key="section_type">FIG</infon><infon key="type">fig_title_caption</infon><offset>4076</offset><text>COVID-19-triggered dyshidrosiform bullous pemphigoid</text></passage><passage><infon key="file">cureus-0014-00000026383-i02.jpg</infon><infon key="id">FIG2</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>4129</offset><text>A and B: Hematoxylin and eosin (20x and 40x) showing subepidermal blistering with eosinophilic infiltrate. C: Perilesional direct immunofluorescence showing linear C3 at the basement membrane zone</text></passage><passage><infon key="file">cureus-0014-00000026383-i02.jpg</infon><infon key="id">FIG2</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>4326</offset><text>COVID-19: coronavirus disease 2019</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">title_1</infon><offset>4362</offset><text>Discussion</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>4373</offset><text>Bullous pemphigoid is an uncommon immunobullous disorder that typically presents in the elderly with generalised pruritic tense blisters on urticated or normal skin backgrounds. It is caused by acquired autoimmune IgG against two hemidesmosomal antigens (BpAg 180 and 230) in patients with underlying genetic predisposition. Dyshidrosiform pemphigoid is a rare clinical variant of bullous pemphigoid where itchy blisters primarily involve the palms and soles and may mimic a vesicular eczema flare-up. This is sometimes followed by typical bullous lesions on other body sites.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>4950</offset><text>Previous reports have suggested that bullous pemphigoid can be triggered by vaccination. Cases of bullous pemphigoid have been reported after the administration of tetanus, rabies, hepatitis B, influenza, meningococcus, and swine flu vaccinations.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>5198</offset><text>Pérez-López et al. have described a case of bullous pemphigoid induced by COMIRNATY® (Pfizer-BioNTech COVID-19 vaccine) three days after the vaccination. COVID-19 vaccination has been reported to trigger flare-ups in three cases of bullous pemphigoid and two cases of pemphigus vulgaris in remission.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>5502</offset><text>In our patient, the diagnosis of bullous pemphigoid was not made on the first admission due to the lack of an immunofluorescence test. Dyshidrosiform bullous pemphigoid can be reliably diagnosed based on the clinical presentation combined with histopathological and immunofluorescence results.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>5796</offset><text>The temporal relationship between the onset of rash and the first dose, and the worsening of rash after the second dose support the hypothesis of a possible causative relationship between the administered vaccine and the appearance of bullous pemphigoid in our patient. Similar to drugs that are well-known triggers for bullous pemphigoid, vaccinations might modify the immune response or alter the antigenic properties of the BMZ, thereby inducing this immunobullous disorder.</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">title_1</infon><offset>6275</offset><text>Conclusions</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>6287</offset><text>This report draws attention to the cutaneous adverse effects of COVID-19 vaccines and the importance to detect and report these complications as the global immunisation efforts continue. Bullous pemphigoid has been reported in the medical literature following COVID-19 vaccinations. We reported a case of dyshidrosiform bullous pemphigoid, an uncommon clinical variant that primarily affects the palms and soles following the administration of the COVID-19 Pfizer-BioNTech vaccine. This immunobullous condition could be caused by the vaccine affecting body immune responses or the antigenic features of the BMZ.</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">footnote</infon><offset>6900</offset><text>The authors have declared that no competing interests exist.</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">title</infon><offset>6961</offset><text>Human Ethics</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">footnote</infon><offset>6974</offset><text>Consent was obtained or waived by all participants in this study</text></passage><passage><infon key="section_type">REF</infon><infon key="type">title</infon><offset>7039</offset><text>References</text></passage><passage><infon key="fpage">2258</infon><infon key="lpage">2276</infon><infon key="name_0">surname:Munro;given-names:AP</infon><infon key="name_1">surname:Janani;given-names:L</infon><infon key="name_2">surname:Cornelius;given-names:V</infon><infon key="pub-id_pmid">34863358</infon><infon key="section_type">REF</infon><infon key="source">Lancet</infon><infon key="type">ref</infon><infon key="volume">398</infon><infon key="year">2021</infon><offset>7050</offset><text>Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial</text></passage><passage><infon key="fpage">172</infon><infon key="lpage">180</infon><infon key="name_0">surname:Gambichler;given-names:T</infon><infon key="name_1">surname:Boms;given-names:S</infon><infon key="name_2">surname:Susok;given-names:L</infon><infon key="pub-id_pmid">34661927</infon><infon key="section_type">REF</infon><infon key="source">J Eur Acad Dermatol Venereol</infon><infon key="type">ref</infon><infon key="volume">36</infon><infon key="year">2022</infon><offset>7265</offset><text>Cutaneous findings following COVID-19 vaccination: review of world literature and own experience</text></passage><passage><infon key="fpage">1432</infon><infon key="name_0">surname:Moro;given-names:F</infon><infon key="name_1">surname:Fania;given-names:L</infon><infon key="name_2">surname:Sinagra;given-names:JL</infon><infon key="name_3">surname:Salemme;given-names:A</infon><infon key="name_4">surname:Di Zenzo;given-names:G</infon><infon key="section_type">REF</infon><infon key="source">Biomolecules</infon><infon key="type">ref</infon><infon key="volume">10</infon><infon key="year">2020</infon><offset>7362</offset><text>Bullous pemphigoid: trigger and predisposing factors</text></passage><passage><infon key="fpage">391</infon><infon key="lpage">399</infon><infon key="name_0">surname:Lo Schiavo;given-names:A</infon><infon key="name_1">surname:Ruocco;given-names:E</infon><infon key="name_2">surname:Brancaccio;given-names:G</infon><infon key="name_3">surname:Caccavale;given-names:S</infon><infon key="name_4">surname:Ruocco;given-names:V</infon><infon key="name_5">surname:Wolf;given-names:R</infon><infon key="pub-id_pmid">23806156</infon><infon key="section_type">REF</infon><infon key="source">Clin Dermatol</infon><infon key="type">ref</infon><infon key="volume">31</infon><infon key="year">2013</infon><offset>7415</offset><text>Bullous pemphigoid: etiology, pathogenesis, and inducing factors: facts and controversies</text></passage><passage><infon key="fpage">438</infon><infon key="lpage">445</infon><infon key="name_0">surname:Cozzani;given-names:E</infon><infon key="name_1">surname:Gasparini;given-names:G</infon><infon key="name_2">surname:Burlando;given-names:M</infon><infon key="name_3">surname:Drago;given-names:F</infon><infon key="name_4">surname:Parodi;given-names:A</infon><infon key="pub-id_pmid">25617817</infon><infon key="section_type">REF</infon><infon key="source">Autoimmun Rev</infon><infon key="type">ref</infon><infon key="volume">14</infon><infon key="year">2015</infon><offset>7505</offset><text>Atypical presentations of bullous pemphigoid: clinical and immunopathological aspects</text></passage><passage><infon key="fpage">0</infon><infon key="name_0">surname:Cohen;given-names:PR</infon><infon key="section_type">REF</infon><infon key="source">Cureus</infon><infon key="type">ref</infon><infon key="volume">12</infon><infon key="year">2020</infon><offset>7591</offset><text>Dyshidrosiform bullous pemphigoid: case reports and review</text></passage><passage><infon key="fpage">153</infon><infon key="lpage">154</infon><infon key="name_0">surname:Fournier;given-names:B</infon><infon key="name_1">surname:Descamps;given-names:V</infon><infon key="name_2">surname:Bouscarat;given-names:F</infon><infon key="name_3">surname:Crickx;given-names:B</infon><infon key="name_4">surname:Belaich;given-names:S</infon><infon key="pub-id_pmid">8776390</infon><infon key="section_type">REF</infon><infon key="source">Br J Dermatol</infon><infon key="type">ref</infon><infon key="volume">135</infon><infon key="year">1996</infon><offset>7650</offset><text>Bullous pemphigoid induced by vaccination</text></passage><passage><infon key="fpage">66</infon><infon key="lpage">68</infon><infon key="name_0">surname:Jindal;given-names:A</infon><infon key="name_1">surname:Nayak;given-names:SU</infon><infon key="name_2">surname:Shenoi;given-names:SD</infon><infon key="name_3">surname:Rao;given-names:R</infon><infon key="name_4">surname:Monappa;given-names:V</infon><infon key="pub-id_pmid">31823906</infon><infon key="section_type">REF</infon><infon key="source">Indian J Dermatol Venereol Leprol</infon><infon key="type">ref</infon><infon key="volume">86</infon><infon key="year">2020</infon><offset>7692</offset><text>Bullous pemphigoid triggered by rabies vaccine</text></passage><passage><infon key="fpage">1</infon><infon key="name_0">surname:Yaron;given-names:Z</infon><infon key="name_1">surname:Alex;given-names:Z</infon><infon key="name_2">surname:Yehoda;given-names:S</infon><infon key="section_type">REF</infon><infon key="source">Immunome Res</infon><infon key="type">ref</infon><infon key="volume">10</infon><infon key="year">2014</infon><offset>7739</offset><text>Infantile bullous pemphigoid following hepatitis B vaccinations</text></passage><passage><infon key="fpage">363</infon><infon key="name_0">surname:Downs;given-names:AM</infon><infon key="name_1">surname:Lear;given-names:JT</infon><infon key="name_2">surname:Bower;given-names:CP</infon><infon key="name_3">surname:Kennedy;given-names:CT</infon><infon key="section_type">REF</infon><infon key="source">Br J Dermatol</infon><infon key="type">ref</infon><infon key="volume">138</infon><infon key="year">1998</infon><offset>7803</offset><text>Does influenza vaccination induce bullous pemphigoid? A report of four cases</text></passage><passage><infon key="fpage">0</infon><infon key="name_0">surname:Navarro-Navarro;given-names:I</infon><infon key="name_1">surname:Jiménez-Gallo;given-names:D</infon><infon key="name_2">surname:Valenzuela-Ubiña;given-names:S</infon><infon key="name_3">surname:Domínguez-Gomez;given-names:M</infon><infon key="name_4">surname:Linares-Barrios;given-names:M</infon><infon key="section_type">REF</infon><infon key="source">Br J Dermatol</infon><infon key="type">ref</infon><infon key="volume">184</infon><infon key="year">2021</infon><offset>7880</offset><text>Infantile bullous pemphigoid following serogroup B meningococcal vaccination</text></passage><passage><infon key="fpage">74</infon><infon key="lpage">76</infon><infon key="name_0">surname:Walmsley;given-names:N</infon><infon key="name_1">surname:Hampton;given-names:P</infon><infon key="pub-id_pmid">22408707</infon><infon key="section_type">REF</infon><infon key="source">J Dermatol Case Rep</infon><infon key="type">ref</infon><infon key="volume">5</infon><infon key="year">2011</infon><offset>7957</offset><text>Bullous pemphigoid triggered by swine flu vaccination: case report and review of vaccine triggered pemphigoid</text></passage><passage><infon key="fpage">0</infon><infon key="lpage">4</infon><infon key="name_0">surname:Pérez-López;given-names:I</infon><infon key="name_1">surname:Moyano-Bueno;given-names:D</infon><infon key="name_2">surname:Ruiz-Villaverde;given-names:R</infon><infon key="section_type">REF</infon><infon key="source">Med Clin (Barc)</infon><infon key="type">ref</infon><infon key="volume">157</infon><infon key="year">2021</infon><offset>8067</offset><text>Bullous pemphigoid and COVID-19 vaccine</text></passage><passage><infon key="fpage">0</infon><infon key="lpage">7</infon><infon key="name_0">surname:Damiani;given-names:G</infon><infon key="name_1">surname:Pacifico;given-names:A</infon><infon key="name_2">surname:Pelloni;given-names:F</infon><infon key="name_3">surname:Iorizzo;given-names:M</infon><infon key="section_type">REF</infon><infon key="source">J Eur Acad Dermatol Venereol</infon><infon key="type">ref</infon><infon key="volume">35</infon><infon key="year">2021</infon><offset>8107</offset><text>The first dose of COVID-19 vaccine may trigger pemphigus and bullous pemphigoid flares: is the second dose therefore contraindicated?</text></passage></document></collection>
